Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.39 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2357856 | 0.77 | KMT2A (0.41) | KMT2ALMNANPC1RAB9APOLB | |
| SCHEMBL10218967 | 0.74 | KMT2A (0.47) | KMT2ALMNANPC1RAB9APOLB | |
| SCHEMBL3475820 | 0.74 | ALDH1A1 (0.41) | KMT2ALMNANPC1RAB9AMAPT | |
| SCHEMBL4941359 | 0.72 | — | — | |
| Acetic Acid SCHEMBL10730639 | 0.70 | PTPN1 (0.46) | KMT2ALMNANPC1RAB9APOLB | |
| SCHEMBL18250665 | 0.66 | PTPN1 (0.43) | KMT2ANPC1RAB9APOLBMAPT | |
| SCHEMBL7186213 | 0.66 | PTPN1 (0.40) | KMT2ANPC1RAB9APOLBMAPT | |
| SCHEMBL7186204 | 0.65 | PTPN1 (0.39) | KMT2ALMNANPC1RAB9APOLB | |
| Dibenzoylmethane SCHEMBL28976283 | 0.65 | KMT2A (0.55) | KMT2ALMNANPC1RAB9APOLB | |
| SCHEMBL4542505 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014164767-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-6949543-B2 | Amide derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| EP-1340750-B1 | AMIDE DERIVATIVES | YAMANOUCHI PHARMA CO LTD (JP) | 2005-08-17 | — | — | EP | disclosed |
| US-20040034232-A1 | Amide derivative | ASTELLAS PHARMA INC. (JP) | 2004-02-19 | — | — | US | disclosed |
| EP-1165494-B1 | HSV PRIMASE INHIBITORS | BOEHRINGER INGELHEIM CA LTD (CA) | 2003-11-05 | — | — | EP | disclosed |
| EP-1340750-A1 | AMIDE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-09-03 | — | — | EP | disclosed |
| EP-1165494-A2 | HSV PRIMASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-01-02 | — | — | EP | disclosed |
| US-6323202-B1 | BENZAMIDE SUBSTITUTES WITH KETONE COMPOUNDS AS ENZYME INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-11-27 | — | — | US | disclosed |
| WO-2000058270-A2 | HSV PRIMASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034232-A1 | Amide derivative | HDAC2, ZC3HAV1, HDAC4 | KMT2A 111/4885LMNA 4369/4885NPC1 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.